How to buy Allergan (AGN) stocks

Allergan is a drug manufacturers - general business based in the US. Allergan shares (AGN) are listed on the NYSE and all prices are listed in US Dollars. Allergan employs 17,400 staff and has a trailing 12-month revenue of around $16.1 billion.

Our top picks for where to buy Allergan stock

Buy Allergan stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Related: Compare the best stock trading platforms in Canada

Allergan stock price (NYSE: AGN)

Use our graph to track the performance of AGN stocks over time.

Allergan stocks at a glance

• Key figures

Information last updated 2020-06-08.

52-week range	$0.00 - $0.00
50-day moving average more info button	$188.84
200-day moving average more info button	$187.66
Wall St. target price	$188.33
PE ratio more info button	N/A
Dividend yield more info button	$2.96 (1.53%)
Earnings per share (TTM) more info button	$-25.50

Is it a good time to buy Allergan stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Is Allergan stock undervalued or overvalued?

Valuing Allergan stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Allergan's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Allergan's PEG ratio

Allergan's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0492. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Allergan's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Allergan's EBITDA

Allergan's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.2 billion.

The EBITDA is a measure of a Allergan's overall financial performance and is widely used to measure a its profitability.

Allergan financials

Revenue TTM	$16.1 billion
Operating margin TTM	6.85%
Gross profit TTM	$13.7 billion
Return on assets TTM	0.74%
Return on equity TTM	-4.15%
Profit margin	-15.44%
Book value	$175.91
Market Capitalization more info button	$63.7 billion

TTM: trailing 12 months

Allergan stock dividends

We're not expecting Allergan to pay a dividend over the next 12 months.

Have Allergan's stocks ever split?

Allergan's stocks were split on a 2:1 basis on 29 October 1997 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Allergan stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Allergan stocks, which in turn could have impacted Allergan's stock price.

Allergan stock price volatility

Over the last 12 months, Allergan's stocks have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Allergan's is 1.1992. This would suggest that Allergan's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Allergan overview

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Allergan is owned by insiders or institutions?
Currently 0.156% of Allergan stocks are held by insiders and 98.255% by institutions. How many people work for Allergan?
Latest data suggests 17,400 work at Allergan. When does the fiscal year end for Allergan?
Allergan's fiscal year ends in December. Where is Allergan based?
Allergan's address is: Clonshaugh Business and Technology Park, Dublin, Ireland, D17 E400 What is Allergan's ISIN number?
Allergan's international securities identification number is: USG0177J1081 What is Allergan's CUSIP number?
Allergan's Committee on Uniform Securities Identification Procedures number is: 942683103

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.